The Nutrient-Dependent O-GlcNAc Modification Controls the Expression of Liver Fatty Acid Synthase

• Published in: Journal of molecular biology Vol. 428; no. 16; pp. 3295 - 3304
• Main Authors: Baldini, Steffi F., Wavelet, Cindy, Hainault, Isabelle, Guinez, Céline, Lefebvre, Tony
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 14.08.2016
• Series: Journal of Molecular Biology
• Subjects: Animals; Cell Line; Chemical Sciences; FAS; Fatty Acid Synthases - metabolism; Food; lipogenesis; Lipogenesis - physiology; liver; Liver - metabolism; Mice; Mice, Inbred C57BL; N-Acetylglucosaminyltransferases - metabolism; O-GlcNAcylation; ob/ob mice; Obesity - metabolism; or physical chemistry; Protein Processing, Post-Translational - physiology; Theoretical and; PBS; DON; SREBP; TBS; liver; LXR; HCD; PTM; OGA; IHH; ob/ob mice; lipogenesis; sWGA; SD; ChREBP; GFAT; USP2A; HBP; FAS; O-GlcNAcylation; qPCR; OGT; Cell Line; Obesity; Liver; N-Acetylglucosaminyltransferases; Post-Translational; Inbred C57BL; Animals; Fatty Acid Synthases; Mice; Protein Processing; Lipogenesis; Food
• ISSN: 0022-2836; 1089-8638; 1089-8638
• DOI: 10.1016/j.jmb.2016.04.035

Liver Fatty Acid Synthase (FAS) is pivotal for de novo lipogenesis. Loss of control of this metabolic pathway contributes to the development of liver pathologies ranging from steatosis to nonalcoholic steatohepatitis (NASH) which can lead to cirrhosis and, less frequently, to hepatocellular carcinoma. Therefore, deciphering the molecular mechanisms governing the expression and function of key enzymes such as FAS is crucial. Herein, we link the availability of this lipogenic enzyme to the nutrient-dependent post-translational modification O-GlcNAc that is thought to be deregulated in metabolic diseases (diabetes, obesity, and metabolic syndrome). We demonstrate that expression and activity of liver FAS correlate with O-GlcNAcylation contents in ob/ob mice and in mice fed with a high-carbohydrate diet both in a transcription-dependent and -independent manner. More importantly, inhibiting the removal of O-GlcNAc residues in mice intraperitoneally injected with the selective and potent O-GlcNAcase (OGA) inhibitor Thiamet-G increases FAS expression. FAS and O-GlcNAc transferase (OGT) physically interact, and FAS is O-GlcNAc modified. Treatment of a liver cell line with drugs or nutrients that elevate the O-GlcNAcylation interferes with FAS expression. Inhibition of OGA increases the interaction between FAS and the deubiquitinase Ubiquitin-specific protease-2a (USP2A) in vivo and ex vivo, providing mechanistic insights into the control of FAS expression through O-GlcNAcylation. Together, these results reveal a new type of regulation of FAS, linked to O-GlcNAcylation status, and advance our knowledge on deregulation of lipogenesis in diverse forms of liver diseases. [Display omitted] •FAS is one of the key enzymes involved in lipogenesis.•In vivo, liver O-GlcNAcylation levels correlate with those of FAS expression and activity.•FAS physically interacts with OGT and is O-GlcNAcylated.•Ex vivo, FAS expression level is increased by drugs and nutrients elevating O-GlcNAcylation.•Inhibition of OGA promotes the interaction of FAS with USP2A.•O-GlcNAcylation is a post-translational modification that controls FAS expression.